IO Biotech announced that an Independent Data Monitoring Committee recommended continuing its Phase 3 trial of the cancer vaccine IO102-IO103 combined with KEYTRUDA, noting no new safety concerns and projecting the primary endpoint of progression-fre
AI Assistant
IO BIOTECH INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.